0001638599-16-000919.txt : 20160523 0001638599-16-000919.hdr.sgml : 20160523 20160523162011 ACCESSION NUMBER: 0001638599-16-000919 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160520 FILED AS OF DATE: 20160523 DATE AS OF CHANGE: 20160523 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CorMedix Inc. CENTRAL INDEX KEY: 0001410098 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1430 HIGHWAY 206 STREET 2: SUITE 200 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 908-517-9500 MAIL ADDRESS: STREET 1: 1430 HIGHWAY 206 STREET 2: SUITE 200 CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lefkowitz Steven W CENTRAL INDEX KEY: 0001313149 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34673 FILM NUMBER: 161669266 MAIL ADDRESS: STREET 1: SIX HARRISON STREET CITY: NEW YORK STATE: NY ZIP: 10013 4 1 doc4_3977.xml PRIMARY DOCUMENT X0306 4 2016-05-20 0 0001410098 CorMedix Inc. CRMD 0001313149 Lefkowitz Steven W C/O CORMEDIX INC. 1430 US HIGHWAY 206, SUITE 200 BEDMINSTER NJ 07921 1 0 0 0 Common Stock, $0.001 par value per share 2016-05-20 4 S 0 14874 2.8627 D 132525 D Common Stock, $0.001 par value per share 2016-05-23 4 M 0 50000 0.68 A 182525 D Common Stock, $0.001 par value per share 2016-05-23 4 S 0 15126 3.00 D 167399 D Common Stock, $0.001 par value per share 174741 I Wade Capital Corporation Money Purchase Plan Common Stock, $0.001 par value per share 10000 I Reporting Person's Wife Stock Option (right to buy) 2.02 2024-01-09 Common Stock, $0.001 par value per share 200000 200000 D Stock Option (right to buy) 2.02 2024-01-09 Common Stock, $0.001 par value per share 30000 30000 D Swries C-3 Non-Voting Convertible Preferred Stock 1 Common Stock, $0.001 par value per share 45000 4500 D Warrant (right to purchase Common Stock) 0.9 2015-01-08 2020-01-08 Common Stock, $0.001 par value per share 22500 22500 D Series C-3 Non-Voting Convertible Preferred Stock 1 Common Stock, $0.001 par value per share 30000 3000 I Wade Capital Corporation Money Purchase Plan Warrant (right to purchase Common Stock) 0.9 2015-01-08 2020-01-08 Common Stock, $0.001 par value per share 15000 15000 I Wade Capital Corporation Money Purchase Plan Stock Option (right to buy) 0.9 2023-03-20 Common Stock, $0.001 par value per share 120000 120000 D Stock Option (right to buy) 0.68 2016-05-23 4 M 0 50000 0.00 D 2022-12-05 Common Stock, $0.001 par value per share 150000 100000 D Stock Option (right to buy) 1.1 2021-08-11 Common Stock, $0.001 par value per share 30000 30000 D Stock Option (right to buy) 5.62 2025-03-01 Common Stock, $0.001 par value per share 50000 50000 D Stock Option (right to buy) 1.91 2017-09-20 Common Stock, $0.001 par value per share 75000 75000 D The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control). The options vested 100% on January 10, 2014. On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock. On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock. These options vest quarterly over two years beginning June 13, 2013. These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013. The options vest in full on the first anniversary of the date of grant. The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof. Alexander M. Donalson by Power of Attorney 2016-05-23